Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Phase 3aglatimagene besadenovecPositive

AI Analysis

Summary

Candel Therapeutics announced extended follow-up data from its Phase 3 trial of aglatimagene besadenovec in localized prostate cancer will be presented at the AUA 2026 Annual Meeting on May 15, 2026, followed by an investor conference call.

Clinical Trial Data

Phase

Outcome Details

Extended follow-up data from Phase 3 trial presented at AUA 2026 Annual Meeting

Importance:6/10

Sentiment:

0.30

Phase 3prostate cancerimmunotherapydata presentationinvestor call

Related Companies

$CADL

Read the original article

Published by GlobeNewswire Clinical Studies on May 4, 2026 12:05 PM

Read Original